vs
Side-by-side financial comparison of Nutex Health, Inc. (NUTX) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($295.9M vs $151.7M, roughly 2.0× Nutex Health, Inc.). Bio-Techne runs the higher net margin — 12.8% vs 7.8%, a 5.0% gap on every dollar of revenue. On growth, Bio-Techne posted the faster year-over-year revenue change (-6.4% vs -41.1%). Over the past eight quarters, Nutex Health, Inc.'s revenue compounded faster (50.0% CAGR vs 4.2%).
Nutex Health Inc. is an American for-profit health care company and operator of healthcare facilities headquartered in Houston, Texas.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
NUTX vs TECH — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $151.7M | $295.9M |
| Net Profit | $11.8M | $38.0M |
| Gross Margin | 30.4% | 64.6% |
| Operating Margin | 20.4% | 18.4% |
| Net Margin | 7.8% | 12.8% |
| Revenue YoY | -41.1% | -6.4% |
| Net Profit YoY | -80.8% | 68.3% |
| EPS (diluted) | $2.34 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $151.7M | $295.9M | ||
| Q3 25 | $267.8M | — | ||
| Q2 25 | $244.0M | $317.0M | ||
| Q1 25 | $211.8M | $316.2M | ||
| Q4 24 | $257.6M | $297.0M | ||
| Q3 24 | $78.8M | $289.5M | ||
| Q2 24 | $76.1M | $306.1M | ||
| Q1 24 | $67.5M | $303.4M |
| Q4 25 | $11.8M | $38.0M | ||
| Q3 25 | $55.4M | — | ||
| Q2 25 | $-17.7M | $-17.7M | ||
| Q1 25 | $21.2M | $22.6M | ||
| Q4 24 | $61.6M | $34.9M | ||
| Q3 24 | $-8.8M | $33.6M | ||
| Q2 24 | $-364.0K | $40.6M | ||
| Q1 24 | $-364.0K | $49.1M |
| Q4 25 | 30.4% | 64.6% | ||
| Q3 25 | 57.8% | — | ||
| Q2 25 | 51.2% | 62.7% | ||
| Q1 25 | 55.9% | 67.9% | ||
| Q4 24 | 55.0% | 65.3% | ||
| Q3 24 | 27.8% | 63.2% | ||
| Q2 24 | 29.7% | 66.4% | ||
| Q1 24 | 15.1% | 67.4% |
| Q4 25 | 20.4% | 18.4% | ||
| Q3 25 | 48.7% | — | ||
| Q2 25 | 13.8% | -7.5% | ||
| Q1 25 | 38.1% | 12.2% | ||
| Q4 24 | 44.4% | 16.0% | ||
| Q3 24 | 12.3% | 13.8% | ||
| Q2 24 | 7.0% | 15.0% | ||
| Q1 24 | 2.1% | 22.1% |
| Q4 25 | 7.8% | 12.8% | ||
| Q3 25 | 20.7% | — | ||
| Q2 25 | -7.3% | -5.6% | ||
| Q1 25 | 10.0% | 7.1% | ||
| Q4 24 | 23.9% | 11.7% | ||
| Q3 24 | -11.2% | 11.6% | ||
| Q2 24 | -0.5% | 13.3% | ||
| Q1 24 | -0.5% | 16.2% |
| Q4 25 | $2.34 | $0.24 | ||
| Q3 25 | $7.76 | — | ||
| Q2 25 | $-2.95 | $-0.11 | ||
| Q1 25 | $3.33 | $0.14 | ||
| Q4 24 | $11.56 | $0.22 | ||
| Q3 24 | $-1.72 | $0.21 | ||
| Q2 24 | $-0.07 | $0.26 | ||
| Q1 24 | $-0.08 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $185.6M | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | $329.4M | $2.0B |
| Total Assets | $918.5M | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $185.6M | $172.9M | ||
| Q3 25 | $166.0M | — | ||
| Q2 25 | $96.7M | $162.2M | ||
| Q1 25 | $84.7M | $140.7M | ||
| Q4 24 | $40.6M | $177.5M | ||
| Q3 24 | $46.9M | $187.5M | ||
| Q2 24 | $40.8M | $152.9M | ||
| Q1 24 | $30.0M | $145.3M |
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M | ||
| Q1 24 | — | $389.0M |
| Q4 25 | $329.4M | $2.0B | ||
| Q3 25 | $317.2M | — | ||
| Q2 25 | $235.3M | $1.9B | ||
| Q1 25 | $176.9M | $2.0B | ||
| Q4 24 | $132.4M | $2.1B | ||
| Q3 24 | $60.4M | $2.1B | ||
| Q2 24 | $62.7M | $2.1B | ||
| Q1 24 | $63.0M | $2.0B |
| Q4 25 | $918.5M | $2.5B | ||
| Q3 25 | $964.5M | — | ||
| Q2 25 | $841.0M | $2.6B | ||
| Q1 25 | $761.9M | $2.6B | ||
| Q4 24 | $655.3M | $2.7B | ||
| Q3 24 | $438.5M | $2.7B | ||
| Q2 24 | $422.4M | $2.7B | ||
| Q1 24 | $404.3M | $2.7B |
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× | ||
| Q1 24 | — | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $70.4M | — |
| Free Cash FlowOCF − Capex | $69.0M | — |
| FCF MarginFCF / Revenue | 45.5% | — |
| Capex IntensityCapex / Revenue | 0.9% | — |
| Cash ConversionOCF / Net Profit | 5.95× | — |
| TTM Free Cash FlowTrailing 4 quarters | $245.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $70.4M | — | ||
| Q3 25 | $99.5M | — | ||
| Q2 25 | $27.3M | $98.2M | ||
| Q1 25 | $51.0M | $41.1M | ||
| Q4 24 | $54.0K | $84.3M | ||
| Q3 24 | $6.8M | $63.9M | ||
| Q2 24 | $13.3M | $75.5M | ||
| Q1 24 | $3.1M | $81.0M |
| Q4 25 | $69.0M | — | ||
| Q3 25 | $99.2M | — | ||
| Q2 25 | $26.5M | $93.3M | ||
| Q1 25 | $50.9M | $31.0M | ||
| Q4 24 | $-341.0K | $77.5M | ||
| Q3 24 | $6.2M | $54.7M | ||
| Q2 24 | $12.7M | $57.5M | ||
| Q1 24 | $2.3M | $64.5M |
| Q4 25 | 45.5% | — | ||
| Q3 25 | 37.0% | — | ||
| Q2 25 | 10.9% | 29.4% | ||
| Q1 25 | 24.0% | 9.8% | ||
| Q4 24 | -0.1% | 26.1% | ||
| Q3 24 | 7.8% | 18.9% | ||
| Q2 24 | 16.7% | 18.8% | ||
| Q1 24 | 3.4% | 21.3% |
| Q4 25 | 0.9% | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | 0.3% | 1.5% | ||
| Q1 25 | 0.0% | 3.2% | ||
| Q4 24 | 0.2% | 2.3% | ||
| Q3 24 | 0.8% | 3.2% | ||
| Q2 24 | 0.7% | 5.9% | ||
| Q1 24 | 1.1% | 5.4% |
| Q4 25 | 5.95× | — | ||
| Q3 25 | 1.80× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 2.40× | 1.82× | ||
| Q4 24 | 0.00× | 2.42× | ||
| Q3 24 | — | 1.90× | ||
| Q2 24 | — | 1.86× | ||
| Q1 24 | — | 1.65× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NUTX
| Hospital Division | $143.7M | 95% |
| Population Health Management Division | $8.0M | 5% |
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
